• News
  • SAN DIEGO
  • BioTech

Ambit Biosciences' revenue down in 2Q

San Diego-based Ambit Biosciences (Nasdaq: AMBI) reported Wednesday revenues in the second quarter of 2014 were $26,000, compared to $11.5 million in the second quarter of 2013.

The company says the decrease was primarily due to the termination of its collaboration with Astellas Pharma, effective September 2013.

Ambit reported cash and equivalents of $52.8 million in the second quarter of 2014 ending June 30, compared to $71.2 million on December 31, 2013. The decrease was primarily due to the use of cash to fund operations, according to Ambit.

Research and development expenses were $7.1 million in the second quarter of this year, compared to $6.7 million in the second quarter of 2013.

The company expects its research and development expenses to continue to increase throughout 2014 as its Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients continues enrollment and treatment of patients.

“We are pleased to have initiated our Quantum-R Phase 3 trial, our most notable achievement of the first half,” said Michael Martino, Ambit's president and CEO. “The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year.”

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.